Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

Core Insights - Eli Lilly's EBGLYSS (lebrikizumab-lbkz) shows promising results in treating moderate-to-severe atopic dermatitis, with approximately 80% of patients achieving or maintaining meaningful skin improvement with less frequent dosing [1][5] - The company has submitted new data to the FDA for a potential label update, which could allow for a maintenance dosing schedule of once every eight weeks [1][3] Group 1: Clinical Data and Efficacy - In the Phase 3 ADjoin extension trial, patients receiving EBGLYSS every eight weeks achieved similar disease control rates as those receiving it every four weeks, with 79% and 86% achieving EASI 75, respectively [5][9] - The study also reported that 62% of patients on the eight-week regimen and 73% on the four-week regimen achieved IGA 0 or 1, indicating significant skin clearance [5][9] - There were no new safety findings or increased risk of immunogenicity associated with the less frequent dosing [5][9] Group 2: Treatment Flexibility and Patient Experience - The new dosing schedule could reduce the treatment burden for patients, allowing for as few as six maintenance doses per year, which may enhance patient adherence and quality of life [2][3] - The interleukin-13 (IL-13) inhibitor mechanism of EBGLYSS targets a key cytokine involved in atopic dermatitis, potentially offering a more effective treatment option for patients [2][20] Group 3: Regulatory and Market Position - Lilly is pursuing an FDA label update for the every-eight-week dosing option, while also exploring a twelve-week dosing regimen in ongoing studies [4][3] - EBGLYSS is positioned as a first-line biologic treatment for moderate-to-severe atopic dermatitis, with strong recommendations from the American Academy of Dermatology [4][8] Group 4: Commercial Strategy and Access - Lilly has secured coverage for EBGLYSS with all three major national pharmacy benefit managers, ensuring access for over 90% of individuals with commercial insurance [25] - The company is also working to expand Medicaid and Medicare coverage as part of its health access initiative [25]